HALO
Halozyme Therapeutics Inc
Price:  
47.39 
USD
Volume:  
1,239,537.00
United States | Biotechnology
Valuation
Overview
Financials
Forecast
Compare
Historical Price
SolvencyDividends
Transactions
People

HALO WACC - Weighted Average Cost of Capital

The WACC of Halozyme Therapeutics Inc (HALO) is 9.2%.

The Cost of Equity of Halozyme Therapeutics Inc (HALO) is 10.50%.
The Cost of Debt of Halozyme Therapeutics Inc (HALO) is 4.25%.

Range Selected
Cost of equity 9.10% - 11.90% 10.50%
Tax rate 11.30% - 18.90% 15.10%
Cost of debt 4.00% - 4.50% 4.25%
WACC 8.0% - 10.3% 9.2%
WACC

HALO WACC calculation

Category Low High
Long-term bond rate 3.9% 4.4%
Equity market risk premium 4.6% 5.6%
Adjusted beta 1.14 1.26
Additional risk adjustments 0.0% 0.5%
Cost of equity 9.10% 11.90%
Tax rate 11.30% 18.90%
Debt/Equity ratio 0.24 0.24
Cost of debt 4.00% 4.50%
After-tax WACC 8.0% 10.3%
Selected WACC 9.2%